Chemomodulatory Effect of the Marine-Derived Metabolite Terrein on the Anticancer Properties of Gemcitabine in Colorectal Cancer Cells

Background: Terrein (Terr) is a bioactive marine secondary metabolite that possesses antiproliferative/cytotoxic properties by interrupting various molecular pathways. Gemcitabine (GCB) is an anticancer drug used to treat several types of tumors such as colorectal cancer; however, it suffers from tumor cell resistance, and therefore, treatment failure. Methods: The potential anticancer properties of terrein, its antiproliferative effects, and its chemomodulatory effects on GCB were assessed against various colorectal cancer cell lines (HCT-116, HT-29, and SW620) under normoxic and hypoxic (pO(2) = 1%) conditions. Further analysis via flow cytometry was carried out in addition to quantitative gene expression and (HNMR)-H-1 metabolomic analysis. Results: In normoxia, the effect of the combination treatment (GCB + Terr) was synergistic in HCT-116 and SW620 cell lines. In HT-29, the effect was antagonistic when the cells were treated with (GCB + Terr) under both normoxic and hypoxic conditions. The combination treatment was found to induce apoptosis in HCT-116 and SW620. Metabolomic analysis revealed that the change in oxygen levels significantly affected extracellular amino acid metabolite profiling. Conclusions: Terrein influenced GCB's anti-colorectal cancer properties which are reflected in different aspects such as cytotoxicity, cell cycle progression, apoptosis, autophagy, and intra-tumoral metabolism under normoxic and hypoxic conditions.

Automated summary

The bioactive marine secondary metabolite Terrein enhances the anticancer properties of gemcitabine (GCB) in colorectal cancer cells, with synergistic effects observed in some cell lines under normoxic conditions. However, the combination treatment has an antagonistic effect in other cell lines and under hypoxic conditions. The combination treatment induces apoptosis and affects extracellular amino acid metabolism.